Emerging Pharmaceutical Market in South Africa - Proposed Introduction of New Drug Regulatory Agency (SAHPRA) to Accelerate Drug Registration Process

GBI Research, June 2012, Pages: 74

GBI Research’s new report, “Emerging Pharmaceutical Market in South Africa - Proposed Introduction of New Drug Regulatory Agency (SAHPRA) to Accelerate Drug Registration Process” provides in-depth analysis of the trends, issues and challenges in South Africa’s pharmaceutical market. The report analyzes the overall pharmaceutical and outsourcing market structure, and provides competitive benchmarking for leading companies. It also analyzes the M&A and strategic partnerships that are shaping the pharmaceutical market. The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Research’s team of industry experts.

South Africa’s pharmaceutical market is one of the most attractive markets in Africa. Some of the main reasons for its rapid growth are the availability of cost-effective and skilled labor, high quality infrastructure, and the introduction of the South African Health Products Regulatory Authority (SAHPRA). Most of the local drug manufacturers and distributors are in the hands of big international pharmaceutical firms. GBI Research valued the South African pharmaceutical market at $3.8 billion in 2011, and expects it to reach $7 billion in 2018 at a Compound Annual Growth Rate (CAGR) of 9.2%. South Africa’s healthcare sector is set to witness a number of new healthcare reform plans in the future, with the primary objective being to reduce the growing drug expenditure by increasing the use of generics. The healthcare system aims to cover the entire population under the National Health Insurance (NHI) scheme, which it will start implementing in a small population of 10 districts by 2012.

GBI Research’s analysis shows that generics accounted for over 60% of the volume of the pharmaceutical market in 2011. Government reforms have encouraged the manufacture and use of generic drugs as a tool to limit drug expenditure and provide low-cost effective public healthcare. The combination of government healthcare policies and numerous active generic manufacturing companies points to an increased generic market share in the forecast period.

Scope

- Overall pharmaceutical and outsourcing market structure in South Africa

- Market characterization, including market size, major regulatory bodies, pricing and reimbursement issues, major distribution channels, and intellectual property rights

- Contract Research Organization (CRO) market growth

- Analysis of the leading segments within the South African pharmaceutical industry

- Key drivers and restraints impacting the market

- Competitive benchmarking of leading companies in the pharmaceutical and CRO markets in South Africa

- Key M&A activities and strategic partnership deals that took place between 2009 and mid-2011

Reasons to buy

- Develop market-entry and market expansion strategies by identifying the leading emerging markets poised for strong growth

- Devise a more tailored country strategy through the understanding of key drivers of and barriers to South Africa’s pharmaceutical market

- Develop key strategic initiatives by understanding the key focus areas of leading companies

- Accelerate and strengthen your market position by identifying key companies for M&A and strategic partnerships"

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction

3 Emerging Pharmaceutical Market: South Africa – Industry Characteristics
3.1 Pharmaceutical Market Size and Growth in South Africa
3.2 Environmental Disease Burden
3.2.1 HIV/AIDS
3.2.2 Tuberculosis
3.3 Patented and Generic Drugs Market Share
3.4 Imports and Exports
3.4.1 Imports
3.4.2 Exports
3.4.3 Balance of Trade
3.5 Key Domestic Players in South Africa
3.5.1 Aspen Pharmacare
3.5.2 Adcock Ingram
3.5.3 Cipla Medpro
3.6 Key Foreign Players in South Africa
3.6.1 Sanofi
3.6.2 Pfizer
3.6.3 Roche
3.6.4 Ranbaxy
3.6.5 GlaxoSmithKline
3.6.6 Merck & Co
3.6.7 Novartis
3.7 Market Drivers and Restraints
3.7.1 Drivers
3.7.2 Restraints
3.8 PESTLE Analysis

4 Emerging Pharmaceutical Market: South Africa – Macroeconomic Environment
4.1 Demographic Analysis
4.1.1 Introduction
4.1.2 Population Size, Growth and Structure
4.1.3 Changes in Life Expectancy at Birth
4.1.4 Infant Mortality Rate
4.1.5 Rural/Urban Distribution
4.1.6 Population by Gender
4.2 Gross Domestic Product
4.3 Healthcare Expenditure
4.4 Healthcare System
4.4.1 Health Workforce and Infrastructure in South Africa

5 Emerging Pharmaceutical Market: South Africa – Healthcare Regulation
5.1 Pharmaceutical Regulation in South Africa
5.2 Intellectual Property Rights
5.3 Health Insurance Coverage
5.4 Pricing and Reimbursement
5.4.1 Pricing
5.4.2 Reimbursement
5.5 Clinical Trials

6 Emerging Pharmaceutical Market: South Africa – Industry Trends
6.1 Strategic Consolidations
6.2 Mergers and Acquisitions
6.2.1 Deals by Year
6.2.2 Deals by Type
6.2.3 Deals by Value
6.2.4 Top M&A Deals
6.3 Licensing Agreements
6.3.1 Top Licensing Deals

7 Emerging Pharmaceutical Market: South Africa – Contract Research Organization Industry
7.1 Contract Research Organizations
7.2 Key International Contract Research Organization Players in South Africa
7.2.1 Quintiles
7.2.2 Pharmaceutical Product Development
7.2.3 Inc Research
7.2.4 Parexel
7.2.5 Icon plc.
7.2.6 PRA International
7.3 Key Domestic Contract Research Organization Players in South Africa
7.3.1 African Clinical Research Organization
7.3.2 OnQ

8 Emerging Pharmaceutical Market: South Africa - Appendix
8.1 Market Definitions
8.2 Abbreviations
8.3 Sources
8.4 Research Methodology
8.4.1 Industry Performance
8.4.2 Macroeconomic Environment
8.4.3 Healthcare Regulations
8.4.4 Industry Trends
8.5 Contact Us
8.6 Disclaimer

1.1 List of Tables
Table 1: Emerging Pharmaceutical Market: South Africa, Market Forecast, 2007–2018
Table 2: Emerging Pharmaceutical Market: South Africa, Causes of Death, 2008
Table 3: Emerging Pharmaceutical Market: South Africa, Causes of Death due to Infectious Diseases, 2008
Table 4: Emerging Pharmaceutical Market: South Africa, HIV/AIDS Population (million), (%), 2001–2011
Table 5: Emerging Pharmaceutical Market: South Africa, Tuberculosis Population, 2001–2011
Table 6: Emerging Pharmaceutical Market: South Africa, Pharmaceutical Imports, 2007–2018
Table 7: Emerging Pharmaceutical Market: South Africa, Pharmaceutical Exports, 2007–2018
Table 8: Revised Timelines for Drug Approval Process by South African Health Products Regulatory Authority
Table 9: Emerging Pharmaceutical Market: South Africa, Population Structure in South Africa, (million), 2000–2025
Table 10: Emerging Pharmaceutical Market: South Africa, Population Parameters, 2009
Table 11: Emerging Pharmaceutical Market: South Africa, BRICS, Rural/Urban Distribution of Population, 2011
Table 12: Emerging Pharmaceutical Market: South Africa, Population by Gender(%), 1990–2025
Table 13: Emerging Pharmaceutical Market: South Africa, Macroeconomic Indicators, 2010 and 2015
Table 14: Emerging Pharmaceutical Market: South Africa, National Healthcare Coverage and Expenditure, 2007
Table 15: Emerging Pharmaceutical Market: South Africa, BRICS, Number of Physicians, 2010
Table 16: Emerging Pharmaceutical Market: South Africa, BRICS, Number of Nursing and Midwifery Personnel, 2010
Table 17: Emerging Pharmaceutical Market: South Africa, BRICS, Number of Dentistry Personnel, 2010
Table 18: Emerging Pharmaceutical Market: South Africa, BRICS, Number of Pharmaceutical Personnel, 2010
Table 19: Emerging Pharmaceutical Market: South Africa, BRICS, Number of Hospital Beds per 10,000 Population, 2009
Table 20: Emerging Pharmaceutical Market: South Africa, Medicines Control Council Registration Fees for New Medicines, South Africa
Table 21: Emerging Pharmaceutical Market: South Africa, Revised Timelines for Drug Approval Process by South African Health Products Regulatory Authority, South Africa
Table 22: Emerging Pharmaceutical Market: South Africa, Government Employees Medical Scheme, South Africa
Table 23: Emerging Pharmaceutical Market: South Africa, Tiered Pricing System, 2010
Table 24: Emerging Pharmaceutical Market: South Africa, Number of Clinical Trials, 2007–2011
Table 25: Emerging Pharmaceutical Market: South Africa, Strategic Consolidations, Deals by Year, 2009–2011
Table 26: Emerging Pharmaceutical Market: South Africa, Recent M&A Deals, 2009–2011
Table 27: Emerging Pharmaceutical Market: South Africa, Recent Licensing Agreements, 2009–2011

1.2 List of Figures
Figure 1: Emerging Pharmaceutical Market: South Africa, Market Forecast, 2007–2018
Figure 2: Emerging Pharmaceutical Market: South Africa, Top 10 Causes of Death (%), 2008
Figure 3: Emerging Pharmaceutical Market: South Africa, Causes of Death due to Infectious Diseases (%), 2008
Figure 4: Emerging Pharmaceutical Market: South Africa, HIV/AIDS Population (million), 2001–2011
Figure 5: Emerging Pharmaceutical Market: South Africa, Deaths due to AIDS, 2001–2011
Figure 6: Emerging Pharmaceutical Market: South Africa, Transmission of HIV/AIDS, (%), 2011
Figure 7: Emerging Pharmaceutical Market: South Africa, Tuberculosis Population, 2001–2011
Figure 8: Emerging Pharmaceutical Market: South Africa, Patented vs. Generic Drugs, by Value, 2011
Figure 9: Emerging Pharmaceutical Market: South Africa, Patented vs. Generic Drugs Market Share %, by Volume, 2011
Figure 10: Emerging Pharmaceutical Market: South Africa, Pharmaceutical Imports, 2007–2018
Figure 11: Emerging Pharmaceutical Market: South Africa, Pharmaceutical Exports, 2007–2018
Figure 12: Emerging Pharmaceutical Market: South Africa, Pharmaceutical Exports and Imports, 2007–2018
Figure 13: Emerging Pharmaceutical Market: South Africa, Aspen Pharmacare, SWOT Analysis, 2011
Figure 14: Emerging Pharmaceutical Market: South Africa, Adcock Ingram, SWOT Analysis, 2011
Figure 15: Emerging Pharmaceutical Market: South Africa, Cipla Medpro, SWOT Analysis, 2011
Figure 16: Emerging Pharmaceutical Market: South Africa, Sanofi, SWOT Analysis, 2011
Figure 17: Emerging Pharmaceutical Market: South Africa, Pfizer, SWOT Analysis, 2011
Figure 18: Emerging Pharmaceutical Market: South Africa, Roche, SWOT Analysis, 2011
Figure 19: Emerging Pharmaceutical Market: South Africa, Ranbaxy, SWOT Analysis, 2011
Figure 20: Emerging Pharmaceutical Market: South Africa, GlaxoSmithKline, SWOT Analysis, 2011
Figure 21: Emerging Pharmaceutical Market: South Africa, Merck and Co., SWOT Analysis, 2011
Figure 22: Emerging Pharmaceutical Market: South Africa, Novartis, SWOT Analysis, 2011
Figure 23: Emerging Pharmaceutical Market: South Africa, Market Drivers, 2011
Figure 24: Emerging Pharmaceutical Market: South Africa, Market Restraints, 2011
Figure 25: Emerging Pharmaceutical Market: South Africa, PESTLE Analysis, 2011
Figure 26: Emerging Pharmaceutical Market: South Africa, Population of BRICS Nations, 2010
Figure 27: Emerging Pharmaceutical Market: South Africa, Population Structure, (million), 2000–2025
Figure 28: Emerging Pharmaceutical Market: South Africa, Life Expectancy at Birth, 1950–2010
Figure 29: Emerging Pharmaceutical Market: South Africa, Infant Mortality Rate, 2001–2011
Figure 30: Emerging Pharmaceutical Market: South Africa, Rural/Urban Distribution of Population, 1990–2009
Figure 31: Emerging Pharmaceutical Market: South Africa, National Healthcare Expenditure, 2008
Figure 32: Emerging Pharmaceutical Market: South Africa, Private Healthcare Expenditure (%), 2010
Figure 33: Emerging Pharmaceutical Market: South Africa, Increase in Government Healthcare Expenditure over the Previous Year (%), 2011
Figure 34: Emerging Pharmaceutical Market: South Africa, BRICS, Number of Physicians per 10,000 Population, 2010
Figure 35: Emerging Pharmaceutical Market: South Africa, BRICS, Number of Nursing and Midwifery Personnel per 10,000 Population, 2010
Figure 36: Emerging Pharmaceutical Market: South Africa, BRICS, Number of Dentistry Personnel per 10,000 Population, 2010
Figure 37: Emerging Pharmaceutical Market: South Africa, BRICS, Number of Pharmaceutical Personnel per 10,000 Population, 2010
Figure 38: Emerging Pharmaceutical Market: South Africa, BRICS, Number of Hospital Beds per 10,000 Population, 2009
Figure 39: Emerging Pharmaceutical Market: South Africa, Number of Clinical Trials, 2007–2011
Figure 40: Emerging Pharmaceutical Market: South Africa, Strategic Consolidation, Deals by Type, (%), 2009–2011
Figure 41: Emerging Pharmaceutical Market: South Africa, Strategic Consolidations, Deals by Year, 2009–2011
Figure 42: Emerging Pharmaceutical Market: South Africa, M&A Deals by Year, 2009–2011
Figure 43: Emerging Pharmaceutical Market: South Africa, M&A Deals by Type, (%), 2009–2011
Figure 44: Emerging Pharmaceutical Market: South Africa, M&A Deals by Value, %, 2009–2011
Figure 45: Emerging Pharmaceutical Market: South Africa, Quintiles, Company Profile, 2011
Figure 46: Emerging Pharmaceutical Market: South Africa, Pharmaceutical Product Development, Company Profile, 2011
Figure 47: Emerging Pharmaceutical Market: South Africa, Inc Research, Company Profile, 2011
Figure 48: Emerging Pharmaceutical Market: South Africa, Parexel, Company Profile, 2011
Figure 49: Emerging Pharmaceutical Market: South Africa, Icon plc, Company Profile, 2011
Figure 50: Emerging Pharmaceutical Market: South Africa, PRA International, Company Profile, 2011
Figure 51: Emerging Pharmaceutical Market: South Africa, African Clinical Research Organization, Company Profile, 2011
Figure 52: Emerging Pharmaceutical Market: South Africa, OnQ, Company Profile, 2011

- Aspen Pharmacare
- Adcock Ingram
- Cipla Medpro
- Sanofi
- Pfizer
- Roche
- Ranbaxy
- GlaxoSmithKline
- Merck & Co
- Novartis

Product Samples

A sample for this product is available. Please Login/Register to download this sample.

Customers who bought this item also bought

• South Africa Diagnostic Imaging Market Outlook to 2017 - Ultrasound Systems, MRI Systems, Computed Tomography Systems, Nuclear Imaging Equipment, X-Ray Systems, Mammography Equipment and Others
• South Africa In Vitro Diagnostics Market Outlook to 2018- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture
• South Africa In Vitro Diagnostics Market Outlook to 2017- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture
• Infectious Immunology Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018
• Overview of the Healthcare Industry in Angola
• Histology And Cytology Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018
• African Infrastructure Tracker: South Africa's Social Infrastructure
• Strategic Analysis of the South African Diabetes Markets
• Genetic Testing Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018
• Infusion Systems Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018